Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11318 Views
-
Last post by NHE
-
- 0 Replies
- 1075 Views
-
Last post by NHE
-
- 0 Replies
- 1868 Views
-
Last post by frodo
-
- 0 Replies
- 1222 Views
-
Last post by frodo
-
- 0 Replies
- 1990 Views
-
Last post by NHE
-
- 0 Replies
- 1677 Views
-
Last post by frodo
-
- 0 Replies
- 1211 Views
-
Last post by NHE
-
- 1 Replies
- 1705 Views
-
Last post by frodo
-
- 0 Replies
- 2300 Views
-
Last post by NHE